Omega 3 fatty acids, no releasing compound and vitamin B12 as neuroprotectant in patients with no dementia
View Patent ↗A method of attenuating, treating or preventing cognitive aging in an individual who does not have dementia includes administering to the individual a therapeutically effective amount of a composition containing an omega-3 fatty acid, a nitric oxide releasing compound, and Vitamin B12. The composition is administered in a daily dose that provides 50 to 500 times the recommended daily requirement (RDA) of Vitamin B12 per day, for example about 200 times the RDA of Vitamin B12 per day. Optionally Vitamin B6 and/or Vitamin B9 can be included in the composition. The method can achieve a benefit that is one or more of decreasing brain atrophy, increasing or maintaining number of synapses, increasing amyloid-β phagocytosis, or decreasing or maintaining neuroinflammation in the non-demented individual. The method can prevent dementia in an individual at risk thereof, for example an elderly human.
1. A method of attenuating, treating, reducing risk of, and/or reducing severity of cognitive aging in a non-demented individual in need thereof or at risk thereof, the method comprising administering to the non-demented individual a therapeutically effective amount of a composition comprising an omega-3 fatty acid, a nitric oxide releasing compound comprising citrulline, and Vitamin B12, and the composition is administered in a daily dose that provides 50 to 500 times the recommended daily requirement (RDA) of Vitamin B12 per day, wherein the composition comprises one or more additional B vitamins selected from the group consisting of Vitamin B1, Vitamin B2, Vitamin B3, Vitamin B5, Vitamin B6, Vitamin B7 and Vitamin B9.
2. The method of claim 1 wherein the daily dose comprises about 150 to 300 times the RDA of Vitamin B12 per day.
3. The method of claim 1 , wherein the non-demented individual is an older adult.
4. The method of claim 1 , wherein the non-demented individual is an elderly human.
5. The method of claim 1 , wherein the composition is orally administered to the non-demented individual daily for at least one month.
6. The method of claim 1 , wherein the omega-3 fatty acid comprises a fatty acid selected from the group consisting of docosahexaenoic acid, eicosapentaenoic acid and mixtures thereof.
7. The method of claim 1 , wherein the composition comprises one or more antioxidants selected from the group consisting of Vitamin C, Vitamin D, Vitamin E, selenium and choline bitartrate.
8. The method of claim 1 , wherein the non-demented individual has a Clinical Dementia Rating (CDR) of 0.5 at baseline.
9. The method of claim 1 , wherein the non-demented individual has a low plasma homocysteine level at baseline of at least 12 μmol/L.
10. The method of claim 1 , wherein the non-demented individual has a risk score in Cardiovascular Risk Factors, Aging and Dementia (CAIDE) of 10 to 15 at baseline.
11. The method of claim 1 , wherein the non-demented individual is amyloid positive on amyloid PET scans at baseline.
12. The method of claim 1 , wherein the non-demented individual has a genotype indicating risk of cognitive decline.
13. A method of attenuating, treating, reducing risk of, and/or reducing severity of cognitive aging in a non-demented individual in need thereof or at risk thereof, the method comprising administering to the non-demented individual a therapeutically effective amount of a composition comprising an omega-3 fatty acid, a nitric oxide releasing compound comprising citrulline, and Vitamin B12, and the composition is administered in a daily dose that provides about 0.4 mg to about 1.0 mg of the Vitamin B12 per day, wherein the composition comprises one or more additional B vitamins selected from the group consisting of Vitamin B1, Vitamin B2, Vitamin B3, Vitamin B5, Vitamin B6, Vitamin B7 and Vitamin B9.
14. A method of achieving one or more of benefits selected from the group consisting of decreasing brain atrophy, increasing or maintaining number of synapses, increasing or maintaining amyloid-P phagocytosis, and decreasing neuroinflammation in a non-demented individual in need thereof, the method comprising administering to the non-demented individual a therapeutically effective amount of a composition comprising an omega-3 fatty acid, a nitric oxide releasing compound comprising citrulline and Vitamin B12, and the composition is administered in a daily dose that provides 50 to 500 times the recommended daily requirement (RDA) of Vitamin B12 per day, wherein the composition comprises one or more additional B vitamins selected from the group consisting of Vitamin B1, Vitamin B2, Vitamin B3, Vitamin B5, Vitamin B6, Vitamin B7 and Vitamin B9.
15. The method of claim 13 , wherein the daily dose provides about 200 times the RDA of the Vitamin B12 per day.
16. The method of claim 13 , wherein the omega-3 fatty acid comprises a fatty acid selected from the group consisting of docosahexaenoic acid, eicosapentaenoic acid and mixtures thereof.
17. The method of claim 14 , wherein the daily dose provides about 200 times the RDA of the Vitamin B12 per day.
18. The method of claim 14 , wherein the omega-3 fatty acid comprises a fatty acid selected from the group consisting of docosahexaenoic acid, eicosapentaenoic acid and mixtures thereof.